

OHE

2nd Floor
Goldings House
Hay's Galleria
2 Hay's Lane
London SE1 2HB

Telephone

+44(0)20 7747 8850

Email

info@ohe.org

Beyond opportunity cost: what are health systems for? The UK-US pharmaceutical agreement and the limits of QALY maximisation

Authored by Graham Cookson

Full Insight available at: <https://www.ohe.org/insights/beyond-opportunity-cost-what-are-health-systems-for-the-uk-us-pharmaceutical-agreement-and-the-limits-of-qaly-maximisation/>

References

ABPI (2025). International comparisons in medicines spending and the link to competitiveness. Association of the British Pharmaceutical Industry. Available from: <https://www.abpi.org.uk/media/blogs/2025/october/international-comparisons-in-medicines-spending-and-the-link-to-competitiveness/>

Acemoglu, D. & Linn, J. (2004). Market size in innovation: theory and evidence from the pharmaceutical industry. *Quarterly Journal of Economics*, 119(3), pp. 1049–1090. Available from: <https://doi.org/10.1162/0033553041502144>

Baumol, W.J. (2012). *The Cost Disease: Why Computers Get Cheaper and Health Care Doesn't*. New Haven: Yale University Press. Available from: <https://doi.org/10.12987/9780300188486>

Bennette, C.S., Basu, A., Ramsey, S.D., Helms, Z. & Bach, P.B. (2019). Health returns to pharmaceutical innovation in the market for oral chemotherapy in response to insurance coverage expansion. *American Journal of Health Economics*, 5(3), pp. 360–375. Available from: <https://ideas.repec.org/a/tpr/amjhec/v5y2019i3p360-375.html>

Blume-Kohout, M.E. & Sood, N. (2013). Market size and innovation: effects of Medicare Part D on pharmaceutical research and development. *Journal of Public Economics*, 97, pp. 327–336. Available from: <https://doi.org/10.1016/j.jpubeco.2012.10.003>

Briggs, A. (2026). A budget apart: the case for ringfencing medicines in the UK. *BMJ*, 393, s755. Available from: <https://www.bmj.com/content/393/bmj.s755>

Briggs, A. & Ruiz, F. (2025). The £25,000 to £35,000 answer. Occam Research, 3 December. Available from: <https://occamresearch.substack.com/p/the-25000-35000-answer>

Bureau of Investigative Journalism (2026). Inside the £64bn pharma deal that could cost more lives than Covid. 13 April. Available from: <https://www.thebureauinvestigates.com/stories/2026-04-13/inside-the-64bn-pharma-deal-that-could-cost-more-lives-than-covid>

Cerda, R.A. (2007). Endogenous innovations in the pharmaceutical industry. Doctoral dissertation, University of Chicago. Available from: <https://rd.springer.com/article/10.1007/s00191-007-0059-3>

Claxton, K. (2025). Impact assessment of the UK—US trade deal: slides and costing tool presented to MPs. Centre for Health Economics, University of York, 10 December. Available from: <https://www.york.ac.uk/che/people/karl-claxton/#research-content>

Claxton, K., Martin, S., Soares, M. et al. (2015). Methods for the estimation of the NICE cost-effectiveness threshold. *Health Technology Assessment*, 19(14). Available from: <https://www.journalslibrary.nihr.ac.uk/hta/HTA19140>

Cookson, G. & Sampson, C. (2024). On the estimation of health opportunity costs. *Health Policy*. Available from: <https://www.sciencedirect.com/journal/health-policy/vol/142/suppl/C>

Cross, S., Claxton, K. & Hill, A. (2026). Health costs of the UK-US trade deal on pharmaceuticals. *BMJ*, 394, e340588. Available from: <https://www.bmj.com/content/394/bmj-2026-340588>

Department of Health and Social Care (2026a). Changes to NICE regulations: cost-effectiveness threshold — consultation document. Updated 3 March 2026. Available from: <https://www.gov.uk/government/consultations/changes-to-nice-regulations-cost-effectiveness-threshold>

Department of Health and Social Care (2026b). UK—US pharmaceutical arrangement: published text. 2 April. Available from: <https://www.gov.uk/government/publications/uk-us-arrangement-on-pharmaceutical-trade-and-pricing>

Dubois, P., de Mouzon, O., Scott-Morton, F. & Seabright, P. (2015). Market size and pharmaceutical innovation. *RAND Journal of Economics*, 46(4), pp. 844—871. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/1756-2171.12113?msocid=2b98bbebd3e86c5e0903af1ad2086dcc>

Finkelstein, A. (2004). Static and dynamic effects of health policy: evidence from the vaccine industry. *Quarterly Journal of Economics*, 119(2), pp. 527—564. Available from: <https://academic.oup.com/qje/article-abstract/119/2/527/1894514?redirectedFrom=fulltext>

Gainsbury, S. & Lomas, J. (2026). The UK government must publish a detailed impact assessment of the US—UK medicines partnership. *BMJ*, 17 April. Available from: <https://www.bmj.com/content/393/bmj.s733>

Hernández-Alava, M., Wailoo, A., Grimm, S., et al. (2018). EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. *Value in Health*, 21(1), pp. 49—56. Available from: <https://pubmed.ncbi.nlm.nih.gov/29304940/>

House of Commons Library (2024). NHS industrial action in England (2022—2024). Briefing Paper CBP-9775. Available from: <https://commonslibrary.parliament.uk/research-briefings/cbp-9775/>

House of Commons Library (2026). What is the UK—US pharmaceuticals deal? Briefing Paper CBP-10850. Available from: <https://commonslibrary.parliament.uk/research-briefings/cbp-10850/>

IQVIA Institute (2025). Drug Expenditure Dynamics 2000—2022. Available from: <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/drug-expenditure-dynamics-2000-2022>

Martin, S., Claxton, K., Lomas, J. & Longo, F. (2023). The impact of different types of NHS expenditure on health: marginal cost per QALY estimates for England, 2016/17. *Health Policy*, 132, 104800. Available from: <https://www.sciencedirect.com/science/article/pii/S0168851023000854>

Mestre-Ferrandiz, J., Sussex, J. & Towse, A. (2012). *The R&D Cost of a New Medicine*. London: Office of Health Economics (Monograph). Available from: <https://ohe.org/publications/rd-cost-new-medicine/>

Myers, K. & Pauly, M. (2019). Endogenous productivity of demand-induced R&D: evidence from pharmaceuticals. *RAND Journal of Economics*, 50(3), pp. 591—614. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/1756-2171.12289?msocid=2b98bbebd3e86c5e0903af1ad2086dcc>

Naci, H., Murphy, P., Woods, B., et al. (2025). Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000—20: a retrospective analysis. *The Lancet*, 405(10472), pp. 50—60. Available from: [https://doi.org/10.1016/S0140-6736\(24\)02352-3](https://doi.org/10.1016/S0140-6736(24)02352-3)

NICE (2025). Statement on revised cost-effectiveness thresholds (£25,000—£35,000 per QALY from April 2026). 1 December. Available from: <https://www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed>

Office for Budget Responsibility (2025). *Economic and Fiscal Outlook*. November 2025. Available from: <https://obr.uk/efo/economic-and-fiscal-outlook-november-2025/>

Office for National Statistics (2024). *UK trade in goods: 2024*. Available from: <https://www.ons.gov.uk/economy/nationalaccounts/balanceofpayments/bulletins/uktrade/december2024>

Office for National Statistics (2024). *UK trade with the United States: 2024*. Available from: <https://www.ons.gov.uk/economy/nationalaccounts/balanceofpayments/articles/uktradewiththeunitedstates/2024>

Office of Health Economics (2026). NICE's new cost-effectiveness threshold: significance, consequences, and unanswered questions. February. Available from: <https://www.ohe.org/insights/nices-new-cost-effectiveness-threshold-significance-consequences-and-unanswered-questions/>

Office for Life Sciences (2025). Life Sciences Sector Plan. Available from:
<https://www.gov.uk/government/publications/life-sciences-sector-plan>

Rake, B. (2017). Determinants of pharmaceutical innovation: the role of technological opportunities revisited. *Journal of Evolutionary Economics*, 27(4), pp. 691–727. Available from:
<https://link.springer.com/article/10.1007/s00191-017-0524-6>

Sampson, C., Leech, A. & Garcia-Lorenzo, B. (2023). Editorial: opportunity costs in health care — cost-effectiveness thresholds and beyond. *Frontiers in Health Services*. Available from:
<https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2023.1293592/full>

Science Media Centre (2025; 2026). Expert reaction to the UK—US pharmaceuticals deal and changes to NICE thresholds. 1 December 2025; 3 April 2026. Available from:
<https://www.sciencemediacentre.org/expert-reaction-to-announcement-on-uk-us-pharmaceuticals-deal-and-changes-to-nices-cost-effectiveness-thresholds/>

Toole, A.A. (2012). The impact of public basic research on industrial innovation: evidence from the pharmaceutical industry. *Research Policy*, 41(1), pp. 1–12. Available from:
<https://doi.org/10.1016/j.respol.2011.06.004>

UK Parliament, Science, Innovation and Technology Committee (2026). Costs of UK—US pharma deal will be met by DHSC, Science Minister confirms. 4 February. Available from:
<https://committees.parliament.uk/committee/135/science-and-technology-committee-commons/news/211725/costs-of-ukus-pharma-deal-will-be-met-by-dhsc-science-minister-confirms/>

Vallance, P. (2026). Letter to Chi Onwurah MP. Health and Social Care Committee, UK Parliament, 30 January. Available from:
<https://committees.parliament.uk/committee/135/science-innovation-and-technology-committee/publications/3/correspondence/>